Spesolimab 450mg/7.5ml solution for infusion vials

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies. OBJECTIVES: To explore the effects of spesolimab treatment in patients with HS. METHODS: This randomized double-blind placebo-controlled proof-of-clinical-concept (PoCC) study was conducted at 25 centres across 12 countries from 3 May 2021 to 21 April 2022. Patients had moderate-to-severe HS for ≥ 1 year before enrolment. Patients were randomized (2 : 1) to receive a loading dose of 3600-mg intravenous spesolimab (1200 mg at weeks 0, 1 and 2) or matching placebo, followed by maintenance with either 1200-mg subcutaneous spesolimab every 2 weeks from weeks 4 to 10 or matching placebo. The primary endpoint was the percentage change from baseline in total abscess and inflammatory nodule (AN) count at week 12. Secondary endpoints were the absolute change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), percentage change from baseline in draining tunnel (dT) count, the proportion of patients achieving a dT count of 0, absolute change from baseline in the revised Hidradenitis Suppurativa Area and Severity Index (HASI-R), the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50), the proportion of patients with ≥ 1 flare (all at week 12) and patient-reported outcomes. RESULTS: In this completed trial, randomized patients (n = 52) received spesolimab (n = 35) or placebo (n = 17). The difference vs. placebo in least squares mean is reported. At week 12, the percentage change in total AN count was similar between treatment arms: -4.1% [95% confidence interval (CI) -31.7 to 23.4]. There was greater numerical improvement in the spesolimab arm, as measured by IHS4 (13.9, 95% CI -25.6 to -2.3); percentage change from baseline in dT count (-96.6%, 95% CI -154.5 to -38.8); and the proportion of patients achieving a dT count of 0 (18.3%, 95% CI -7.9 to 37.5). Spesolimab treatment also improved HASI-R and HiSCR50 vs. placebo. Spesolimab demonstrated a favourable safety profile, similar to that observed in trials in other diseases. CONCLUSIONS: This exploratory PoCC study supports the development of spesolimab as a new therapeutic option in HS.

Abstract licence: CC BY

Introduction: Generalized pustular psoriasis (GPP) and bullous pemphigoid (BP) are two distinct but occasionally coexisting inflammatory skin disorders. Their simultaneous presence presents diagnostic and therapeutic challenges. Spesolimab and dupilumab are novel biologics targeting the IL-36 and IL-4/IL-13 pathways, respectively. However, their sequential use in treating GPP with BP has not been previously reported. Case Presentation: We report a 58-year-old man with a 10-year history of psoriasis who developed acute GPP followed by BP. Initial acitretin therapy resolved pustules but not bullae. A single dose of intravenous spesolimab led to rapid improvement of systemic symptoms and pustular lesions. Persistent bullae were subsequently treated with dupilumab (600 mg loading dose, then 300 mg biweekly), resulting in complete resolution within 2 months. The patient remained relapse-free for 6 months, with no adverse events. Conclusion: This case highlights the potential of sequential spesolimab and dupilumab therapy as an effective and safe approach for managing GPP coexisting with BP. Targeting distinct inflammatory pathways may provide a new treatment option for complex dermatological comorbidities.

Abstract licence: CC BY-NC

) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. This article summarizes the milestones in the development of spesolimab leading to this first approval for GPP flares.

Abstract licence: CC BY-NC

Pyoderma gangrenosum (PG) is a rare, inflammatory neutrophilic disease that is characterized by rapidly progressing, painful skin ulcers with peripheral, violaceous erythema and undermined borders.1Min M.S. Kus K. Wei N. et al.Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study.Br J Dermatol. 2022; 186: 1035-1037https://doi.org/10.1111/bjd.20967Crossref PubMed Scopus (4) Google Scholar, 2Xu A. Balgobind A. Strunk A. Garg A. Alloo A. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis.J Am Acad Dermatol. 2020; 83: 425-429https://doi.org/10.1016/j.jaad.2019.08.001Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar, 3Alavi A. French L.E. Davis M.D. Brassard A. Kirsner R.S. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment.Am J Clin Dermatol. 2017; 18: 355-372https://doi.org/10.1007/s40257-017-0251-7Crossref PubMed Scopus (173) Google Scholar While the pathophysiology of PG has not been fully elucidated, pathogenesis has been largely attributed to pathergy. Upon trauma, keratinocytes release interleukin 36 (IL-36) which is thought to play a role in PG pathogenesis and neutrophil recruitment.4Henry C.M. Sullivan G.P. Clancy D.M. Afonina I.S. Kulms D. Martin S.J. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines.Cell Rep. 2016; 14: 708-722https://doi.org/10.1016/j.celrep.2015.12.072Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar,5Kolios A.G.A. Maul J.-T. Meier B. et al.Canakinumab in adults with steroid-refractory pyoderma gangrenosum.Br J Dermatol. 2015; 173: 1216-1223Crossref PubMed Scopus (78) Google Scholar To date, there is no standardized treatment for PG. Rapidly progressing cases require early systemic therapies such as prednisone, cyclosporine and anti-tumor necrosis factor-α therapies to contain lesions and halt spread.3Alavi A. French L.E. Davis M.D. Brassard A. Kirsner R.S. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment.Am J Clin Dermatol. 2017; 18: 355-372https://doi.org/10.1007/s40257-017-0251-7Crossref PubMed Scopus (173) Google Scholar,6Tan M.H. Gordon M. Lebwohl O. George J. Lebwohl M.G. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.Arch Dermatol. 2001; 137: 930-933PubMed Google Scholar, 7Brooklyn T.N. Dunnill M.G. Shetty A. et al.Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.Gut. 2006; 55: 505-509https://doi.org/10.1136/gut.2005.074815Crossref PubMed Scopus (491) Google Scholar, 8Pomerantz R.G. Husni M.E. Mody E. Qureshi A.A. Adalimumab for treatment of pyoderma gangrenosum.Br J Dermatol. 2007; 157: 1274-1275https://doi.org/10.1111/j.1365-2133.2007.08212.xCrossref PubMed Scopus (52) Google Scholar Spesolimab is an interleukin (IL)-36 receptor blocker that was recently approved for generalized pustular psoriasis (GPP).9Bachelez H. Choon S.E. Marrakchi S. et al.Trial of spesolimab for generalized pustular psoriasis.N Engl J Med. 2021; 385: 2431-2440https://doi.org/10.1056/NEJMoa2111563Crossref PubMed Scopus (82) Google Scholar Bachelez et al9Bachelez H. Choon S.E. Marrakchi S. et al.Trial of spesolimab for generalized pustular psoriasis.N Engl J Med. 2021; 385: 2431-2440https://doi.org/10.1056/NEJMoa2111563Crossref PubMed Scopus (82) Google Scholar demonstrated in a phase 2 randomized trial that spesolimab treatment resulted in significant clearing of GPP lesions compared to placebo. Given similar mechanisms, we hypothesized that targeting IL-36 in refractory, ulcerative, PG may also result in resolution of a patients’ lesions. Prior to its approval, spesolimab was obtained for emergency investigational novel drug use in PG (eIND 163533). Permission to administer spesolimab to patient #1 was approved by our institutional review board and the Food and Drug Administration for 4 doses of 900 mg every 4 weeks for 16 weeks. Patient #2 was infused after Food and Drug Administration approval of spesolimab for GPP flares and was prescribed for off-label use. A 75-year-old male with no significant past medical history presented to the dermatology clinic with a 4-month history of non-healing, growing ulcers subsequent to Mohs surgery for basal cell and squamous cell carcinomas on his left ear, right cheek, chest, right forehead, and left temple. A biopsy of the sites revealed predominantly neutrophilic infiltrate with no signs of infection. At this time, the patient was diagnosed with postoperative, ulcerative PG. Our patient failed 8 months of prednisone therapy (ranging from 60 mg/d-20 mg/d), 3 months of adalimumab 40 mg every 2 weeks and 1 month of adalimumab 40 mg weekly therapy, 1 month of cyclosporine 5 mg/kg therapy, and 3 rounds of intralesional triamcinolone injections. Attempts to taper immunosuppressive medication resulted in disease flare and enlarging lesions. Thus, the patient initiated experimental spesolimab treatment while continuing 30 mg/d prednisone and cyclosporine 5 mg/kg/day. When the patient returned for his second treatment at week 5, he was found to have profound regression of lesion size on his left face, right cheek, and chest (Fig 1). Skin over the crater-like lesion on his right cheek had fully re-epithelized. Purulent discharge had resolved and the patient reported resolution of pain. The patient tolerated a rapid taper of prednisone from 60 mg daily to 3 mg daily and cyclosporine from 5 mg/kg/d to 1.5 mg/kg/d over 5 weeks with dramatic improvement in his condition. He completed 4 900 mg spesolimab infusions and saw complete resolution of 1 of his 4 lesions and significant continued improvement in the remaining lesions. Today, he is maintained on every 4-week spesolimab 900 mg infusions and low dose prednisone and cyclosporine treatment given his extensive disease. The patient continues to improve. Of note, the patient developed epididymitis at week 3 of treatment. He was treated with a 1-month course of doxycycline and resumed treatment without any further complications over the 16-week treatment period. A 39-year-old female with a complex medical history of systemic lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis, and scleroderma presented to clinic with multiple, non-healing ulcers on her upper and lower extremities upon stopping long term use mycophenolate mofetil and prednisone. The patient’s treatment regimen consisted of cyclosporine 4 mg/kg, prednisone 60 mg/d, hydroxychloroquine 200 mg/d, and intravenous immune globulin 2 g/kg every 4 weeks. Biopsy of her lesions showed ulceration with suppurative inflammation with no sign of infectious etiology. Due to the patient’s refractory disease, 900 mg spesolimab was administered while maintaining the patient on cyclosporine 4 mg/kg and 30 mg/d prednisone, and 400 mg/d hydroxychloroquine. Within 48 hours of spesolimab infusion, the patient had reduction in oozing of the ulcers on arms and legs with dramatic improvement in pain. In the following weeks, the size of the ulcers began to reduce with significant re-epithelization of the ulcer base (Fig 2). The patient ultimately only needed 2 900 mg spesolimab infusions separated by 4 weeks. She saw complete resolutions of her lesions and was tapered off cyclosporine and remains on 20 mg/d prednisone and 200 mg hydroxychloroquine for her other rheumatological conditions. No adverse effects were observed during or after spesolimab treatment. IL-36 is a member of the interleukin 1 cytokine family, which has been implicated in neutrophilic inflammation and the pathogenesis of PG.4Henry C.M. Sullivan G.P. Clancy D.M. Afonina I.S. Kulms D. Martin S.J. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines.Cell Rep. 2016; 14: 708-722https://doi.org/10.1016/j.celrep.2015.12.072Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar,5Kolios A.G.A. Maul J.-T. Meier B. et al.Canakinumab in adults with steroid-refractory pyoderma gangrenosum.Br J Dermatol. 2015; 173: 1216-1223Crossref PubMed Scopus (78) Google Scholar In response to IL-36, keratinocytes increase pro-inflammatory signals and skew T cell-differentiation.4Henry C.M. Sullivan G.P. Clancy D.M. Afonina I.S. Kulms D. Martin S.J. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines.Cell Rep. 2016; 14: 708-722https://doi.org/10.1016/j.celrep.2015.12.072Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar,10Carrier Y. Ma H.L. Ramon H.E. et al.Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis.J Invest Dermatol. 2011; 131: 2428-2437https://doi.org/10.1038/jid.2011.234Abstract Full Text Full Text PDF PubMed Scopus (330) Google Scholar,11Yuan Z.C. Xu W.D. Liu X.Y. Liu X.Y. Huang A.F. Su L.C. Biology of IL-36 signaling and its role in systemic inflammatory diseases.Front Immunol. 2019; 10: 2532https://doi.org/10.3389/fimmu.2019.02532Crossref PubMed Scopus (59) Google Scholar Taken together, IL-36 affects both the innate and adaptive immune system leading to an unrelenting, pro-inflammatory cycle (Fig 3). We hypothesize that in our patients spesolimab effectively blocked the IL-36 receptor and thereby halted the PG inflammatory cycle. Our patients’ rapid response to spesolimab with significant regeneration of the epithelium within weeks, further suggests that IL-36 plays a central role in the pathogenesis of PG and likely other neutrophilic diseases. Limitations to be considered are that our patients were treated with concomitant immunosuppressive therapies given the extent of their disease. However, both patients experienced noticeable improvement in their condition within 72 hours of infusion, suggesting a direct effect of spesolimab. Spesolimab is a new treatment; thus, long-term effects of the drug are unknown. During clinical trials for GPP, there were no adverse events that led to discontinuation of the drug.9Bachelez H. Choon S.E. Marrakchi S. et al.Trial of spesolimab for generalized pustular psoriasis.N Engl J Med. 2021; 385: 2431-2440https://doi.org/10.1056/NEJMoa2111563Crossref PubMed Scopus (82) Google Scholar Serious adverse events consist of drug reaction with eosinophilia, urinary tract infection, and drug-induced hepatic injury, and arthritis.9Bachelez H. Choon S.E. Marrakchi S. et al.Trial of spesolimab for generalized pustular psoriasis.N Engl J Med. 2021; 385: 2431-2440https://doi.org/10.1056/NEJMoa2111563Crossref PubMed Scopus (82) Google Scholar Further studies will be important to evaluate long-term safety and establish a new line of treatment for patients suffering from this debilitating disease. Dr Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc. Dr Lebwohl is also a consultant for AnaptysBio, Arcutis, Inc, Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc, Facilitatation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Hexima Ltd, Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial. Dr Khattri is an employee of Mount Sinai and receives research funds from Leo Pharma, Abbvie, Bristol Myers Squibb, Pfizer, Celgene, and Acelyrin. Dr Khattri is also a consultant for Leo, Abbvie, Eli Lilly, Janssen, Regeneron, Sanofi, and UCB. Author Guénin has no conflicts of interest to declare.

Abstract licence: CC BY

Zusammenfassung Die generalisierte pustulöse Psoriasis (GPP) ist eine inflammatorische Erkrankung, die prinzipiell lebensbedrohlich verlaufen kann. Im Gegensatz zur „klassischen“ Psoriasis (Psoriasis vulgaris) geht diese mit einer sterilen Pustelbildung auf erythematöser Haut einher. Bislang gab es in Europa keine suffiziente, zugelassene Therapieoption, sodass die für die Psoriasis vulgaris eingesetzten Medikamente auch bei der GPP Verwendung fanden. Neuere Studien belegen, dass bei der GPP oft eine Mutation des Interleukin-36-Rezeptor-Antagonisten (IL-36Ra) zu einer gesteigerten Inflammation und entsprechend zur Krankheitsaktivität führt. Wir berichten den Fall einer schweren GPP mit einer kompletten Remission nach 2‑maliger Gabe von Spesolimab, einem neuen Interleukin-36-Rezeptor-Antikörper.

Abstract licence: CC BY